Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

That is perhaps why there has been so much buzz surrounding the class of drug known as a GLP-1 agonist.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

"It is estimated that by 2030, 30 million GLP-1 [receptor agonist] prescriptions will have been dispensed in the U.S. Despite the rarity of NAION, the large number of users of these drugs can ...

Taking a GLP-1 may help treat sleep apnea since obesity is one of many factors that increases your likelihood of the sleep ...